Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801
Shots:
- Evotec to receive a up front as well as research funding for biomarker development and CMC and is eligible to receive $361.21M as clinical & commercial milestones along with royalties on the net sales of EVT801- which will be shared with Sanofi (partner in the discovery and the development of EVT801)
- Kazia to get an exclusive WW license for research- development- and commercialization of EVT801. Kazia plans to evaluate EVT801 both as monothx. and in combination with immunotherapy for oncology indications
- Evotec will provide CMC and manage the P-I trial of the therapy while Kazia will responsible for subsequent clinical evaluation & commercialization of EVT801
Ref: Evotec | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com